FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221048920> ?p ?o ?g. }

• W4221048920 endingPage "496" @default.
• W4221048920 startingPage "490" @default.
• W4221048920 abstract "Background Anti-tumour necrosis factor (anti-TNF) therapies are the most commonly used biologics for inflammatory bowel disease (IBD), but for patients with a comorbidity, newer agents may be a more appropriate treatment choice. Aims To investigate the impact of comorbidities in patients with IBD, on first-line biologic prescribing habits of IBD-specialist healthcare practitioners in the UK. Methods IBD-specialist physicians and nurses were asked to answer an online survey, considering different prescribing scenarios in ulcerative colitis (UC) and Crohn’s disease (CD). Respondents could indicate a preference for anti-TNFs or newer biologics, both in the absence and presence of 10 common comorbidities. Results A total of 120 IBD-specialist healthcare professionals (HCPs) completed the survey. In the absence of comorbidities, anti-TNFs were favoured; infliximab was the preferred first-line biologic in both UC and CD (43% and 37% of respondents, respectively). On introducing comorbidities, the largest shift in prescribing behaviour was for vedolizumab, with preference increasing by 27% and 21%, compared with infliximab, which fell by 14% and 9% in UC and CD, respectively. Chronic/recurring infection (46%), congestive heart failure (≤44%) and malignancies (≤43%) were the most commonly selected comorbidities for vedolizumab treatment. Conclusions Clinicians adapt their biologic prescribing habits in patients with IBD with comorbidities, considering known contraindications and precautions. A preference for vedolizumab is evident in many cases, however, for several comorbid scenarios, including demyelinating disorders, chronic obstructive pulmonary disease and malignancy, anti-TNFs are prescribed despite known risks. It is important that continual re-evaluation of the IBD treatment landscape is undertaken by HCPs, in alignment with recommendations in published guidelines." @default.
• W4221048920 created "2022-04-03" @default.
• W4221048920 creator A5058391654 @default.
• W4221048920 creator A5059369253 @default.
• W4221048920 creator A5072882675 @default.
• W4221048920 creator A5076631930 @default.
• W4221048920 creator A5091245648 @default.
• W4221048920 date "2022-03-17" @default.
• W4221048920 modified "2023-10-03" @default.
• W4221048920 title "Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK" @default.
• W4221048920 cites W1410441244 @default.
• W4221048920 cites W1509905658 @default.
• W4221048920 cites W1697737982 @default.
• W4221048920 cites W1991334020 @default.
• W4221048920 cites W1995338823 @default.
• W4221048920 cites W1996136023 @default.
• W4221048920 cites W2011837830 @default.
• W4221048920 cites W2020640954 @default.
• W4221048920 cites W2030277915 @default.
• W4221048920 cites W2052476019 @default.
• W4221048920 cites W2064485014 @default.
• W4221048920 cites W2077531651 @default.
• W4221048920 cites W2080450248 @default.
• W4221048920 cites W2102087425 @default.
• W4221048920 cites W2126807394 @default.
• W4221048920 cites W2131632358 @default.
• W4221048920 cites W2159513257 @default.
• W4221048920 cites W2162805528 @default.
• W4221048920 cites W2291705929 @default.
• W4221048920 cites W2301614008 @default.
• W4221048920 cites W2413203763 @default.
• W4221048920 cites W2427633307 @default.
• W4221048920 cites W2583633660 @default.
• W4221048920 cites W2735524273 @default.
• W4221048920 cites W2754846891 @default.
• W4221048920 cites W2767910653 @default.
• W4221048920 cites W2809894743 @default.
• W4221048920 cites W2887951414 @default.
• W4221048920 cites W2897242856 @default.
• W4221048920 cites W2897827268 @default.
• W4221048920 cites W2918167241 @default.
• W4221048920 cites W2953592136 @default.
• W4221048920 cites W2976362764 @default.
• W4221048920 cites W2976731348 @default.
• W4221048920 cites W3168298113 @default.
• W4221048920 cites W3206229337 @default.
• W4221048920 cites W4205253993 @default.
• W4221048920 cites W4210258765 @default.
• W4221048920 cites W4229808289 @default.
• W4221048920 cites W4233817719 @default.
• W4221048920 cites W4293777482 @default.
• W4221048920 doi "https://doi.org/10.1136/flgastro-2021-101995" @default.
• W4221048920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36250175" @default.
• W4221048920 hasPublicationYear "2022" @default.
• W4221048920 type Work @default.
• W4221048920 citedByCount "2" @default.
• W4221048920 countsByYear W42210489202023 @default.
• W4221048920 crossrefType "journal-article" @default.
• W4221048920 hasAuthorship W4221048920A5058391654 @default.
• W4221048920 hasAuthorship W4221048920A5059369253 @default.
• W4221048920 hasAuthorship W4221048920A5072882675 @default.
• W4221048920 hasAuthorship W4221048920A5076631930 @default.
• W4221048920 hasAuthorship W4221048920A5091245648 @default.
• W4221048920 hasBestOaLocation W42210489201 @default.
• W4221048920 hasConcept C126322002 @default.
• W4221048920 hasConcept C177713679 @default.
• W4221048920 hasConcept C1862650 @default.
• W4221048920 hasConcept C2776207728 @default.
• W4221048920 hasConcept C2777138892 @default.
• W4221048920 hasConcept C2778260677 @default.
• W4221048920 hasConcept C2778715236 @default.
• W4221048920 hasConcept C2779134260 @default.
• W4221048920 hasConcept C2779159551 @default.
• W4221048920 hasConcept C2779280984 @default.
• W4221048920 hasConcept C2780479503 @default.
• W4221048920 hasConcept C71924100 @default.
• W4221048920 hasConceptScore W4221048920C126322002 @default.
• W4221048920 hasConceptScore W4221048920C177713679 @default.
• W4221048920 hasConceptScore W4221048920C1862650 @default.
• W4221048920 hasConceptScore W4221048920C2776207728 @default.
• W4221048920 hasConceptScore W4221048920C2777138892 @default.
• W4221048920 hasConceptScore W4221048920C2778260677 @default.
• W4221048920 hasConceptScore W4221048920C2778715236 @default.
• W4221048920 hasConceptScore W4221048920C2779134260 @default.
• W4221048920 hasConceptScore W4221048920C2779159551 @default.
• W4221048920 hasConceptScore W4221048920C2779280984 @default.
• W4221048920 hasConceptScore W4221048920C2780479503 @default.
• W4221048920 hasConceptScore W4221048920C71924100 @default.
• W4221048920 hasIssue "6" @default.
• W4221048920 hasLocation W42210489201 @default.
• W4221048920 hasLocation W42210489202 @default.
• W4221048920 hasLocation W42210489203 @default.
• W4221048920 hasLocation W42210489204 @default.
• W4221048920 hasOpenAccess W4221048920 @default.
• W4221048920 hasPrimaryLocation W42210489201 @default.
• W4221048920 hasRelatedWork W2587196664 @default.
• W4221048920 hasRelatedWork W2605674307 @default.
• W4221048920 hasRelatedWork W2790575954 @default.

• next